MX360980B - Una composición farmacéutica para la estimulación de la angiogénesis. - Google Patents
Una composición farmacéutica para la estimulación de la angiogénesis.Info
- Publication number
- MX360980B MX360980B MX2015002658A MX2015002658A MX360980B MX 360980 B MX360980 B MX 360980B MX 2015002658 A MX2015002658 A MX 2015002658A MX 2015002658 A MX2015002658 A MX 2015002658A MX 360980 B MX360980 B MX 360980B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- plasmid dna
- vegf165
- pcmv
- cryoprotectant
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 230000026341 positive regulation of angiogenesis Effects 0.000 title 1
- 239000013612 plasmid Substances 0.000 abstract 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 3
- 239000002577 cryoprotective agent Substances 0.000 abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica para la inducción de crecimiento en el tejido del vaso sanguíneo que contiene el ADN plasmático purificado que codifica un factor de crecimiento endotelial vascular (VEGF, por sus siglas en inglés) y excipientes farmacéuticamente aceptables que incluyen un crioprotector como un vehiculo y/o un estabilizar el pH en el intervalo de 7.0 a 9.0. en cantidades eficaces. Tambien se proporciona un método de almacenamiento de ADN plasmático purificado con una solución de al menos uno crioprotectores que tienen propiedades de un vehiculo y/o un estabilizador de Ph en el intervalo de pH de 7.9-9.0. La solución se liofiliza y se almacena de +2 a +8°C. El ADN superenrollado pCMV-VEGFI65 puede usarse que es producido cultivando una cepa de Escherichia coli TOP1Oau/pCMV-VEGF165. La composición farmacéutica es administrada a un humano en cantidades suficientes para proporcionar un efecto terapéutico necesario. La composición farmacéutica proporcionada del ADN plasmático pCMV-VEGF165 no cambia significativamente las propiedades de la sustancia activa cuando se almacena durante un largo tiempo a una temperatura de +2 a +8°C.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2012137126/10A RU2542385C2 (ru) | 2012-08-31 | 2012-08-31 | Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека |
| PCT/RU2013/000669 WO2014035289A1 (en) | 2012-08-31 | 2013-08-02 | A pharmaceutical composition for stimulation of angiogenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015002658A MX2015002658A (es) | 2015-09-25 |
| MX360980B true MX360980B (es) | 2018-11-22 |
Family
ID=50183970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015002658A MX360980B (es) | 2012-08-31 | 2013-08-02 | Una composición farmacéutica para la estimulación de la angiogénesis. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9616103B2 (es) |
| EP (1) | EP2890777B1 (es) |
| CN (1) | CN105308173B (es) |
| BR (1) | BR112015002522B1 (es) |
| CA (1) | CA2881799C (es) |
| ES (1) | ES2621675T3 (es) |
| HU (1) | HUE032520T2 (es) |
| MX (1) | MX360980B (es) |
| PL (1) | PL2890777T3 (es) |
| RU (1) | RU2542385C2 (es) |
| SI (1) | SI2890777T1 (es) |
| WO (1) | WO2014035289A1 (es) |
| ZA (1) | ZA201500909B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2558294C1 (ru) * | 2014-09-16 | 2015-07-27 | Общество с ограниченной ответственностью "НекстГен" | Кодон-оптимизированная рекомбинантная плазмида, способ стимуляции регенерации периферического нерва, способ лечения поврежденного нерва человека |
| RU2612497C2 (ru) | 2015-05-26 | 2017-03-09 | Общество с ограниченной ответственностью "НекстГен" | Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf |
| RU2694826C1 (ru) * | 2018-06-05 | 2019-07-17 | Юрий Валентинович Червяков | Способ лечения хронической ишемии нижних конечностей атеросклеротического генеза при окклюзии артерий голени |
| US12493007B2 (en) | 2018-08-08 | 2025-12-09 | Brightspec, Inc. | Methods and apparatus for low-volatility sampling |
| CN110760542B (zh) * | 2019-11-18 | 2022-07-26 | 天津大学 | 一种共表达znf580和vegf165双基因的质粒及应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613563B1 (en) * | 1997-03-14 | 2003-09-02 | Selective Gentics, Inc. | Viral vectors with modified tropism |
| US6627436B2 (en) * | 1997-10-31 | 2003-09-30 | Stratagene | Vector for gene expression in prokaryotic and eukaryotic systems |
| EP1061955B1 (en) * | 1998-03-13 | 2005-05-04 | Wyeth | Polynucleotide composition, method of preparation, and use thereof |
| WO2000047235A2 (en) * | 1999-02-10 | 2000-08-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of stimulating angiogenesis |
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7288521B2 (en) | 2000-04-06 | 2007-10-30 | Franco Wayne P | Growth factor therapy mobilization of stem cells into the peripheral blood |
| CN1351055A (zh) | 2000-10-26 | 2002-05-29 | 上海博德基因开发有限公司 | 一种新的多肽——人的血管内皮生长因子165受体(vegf－165r)10.67和编码这种多肽的多核苷酸 |
| US7981863B2 (en) * | 2001-09-19 | 2011-07-19 | Neuronova Ab | Treatment of Parkinson's disease with PDGF |
| CN100431611C (zh) | 2002-07-04 | 2008-11-12 | 朱静亚 | 多肽－脂质体与人血管内皮生长因子基因重组质粒复合物及用途 |
| US7259149B2 (en) * | 2002-12-02 | 2007-08-21 | Anges Mg, Inc. | Methods for treating or preventing angiogenesis-dependent symptoms |
| MX2007003214A (es) * | 2004-09-17 | 2007-10-11 | Centelion | Formulaciones liquidas estables de adn plasmidico. |
| RU2297848C2 (ru) * | 2005-05-11 | 2007-04-27 | Александр Веньяминович Иткес | Генно-инженерная конструкция vegf-ибмед (vegf-ibmed) |
| ES2338400B1 (es) | 2008-05-06 | 2011-09-14 | David Benet Ferrus | Conjunto de moleculas antiangiogenicas y su uso. |
| US8367350B2 (en) * | 2009-04-29 | 2013-02-05 | Morehouse School Of Medicine | Compositions and methods for diagnosis, prognosis and management of malaria |
-
2012
- 2012-08-31 RU RU2012137126/10A patent/RU2542385C2/ru active
-
2013
- 2013-08-02 MX MX2015002658A patent/MX360980B/es active IP Right Grant
- 2013-08-02 US US14/423,532 patent/US9616103B2/en active Active
- 2013-08-02 SI SI201330595A patent/SI2890777T1/sl unknown
- 2013-08-02 ES ES13832746.5T patent/ES2621675T3/es active Active
- 2013-08-02 EP EP13832746.5A patent/EP2890777B1/en active Active
- 2013-08-02 PL PL13832746T patent/PL2890777T3/pl unknown
- 2013-08-02 BR BR112015002522-6A patent/BR112015002522B1/pt active IP Right Grant
- 2013-08-02 CN CN201380045032.7A patent/CN105308173B/zh active Active
- 2013-08-02 CA CA2881799A patent/CA2881799C/en active Active
- 2013-08-02 HU HUE13832746A patent/HUE032520T2/en unknown
- 2013-08-02 WO PCT/RU2013/000669 patent/WO2014035289A1/en not_active Ceased
-
2015
- 2015-02-09 ZA ZA2015/00909A patent/ZA201500909B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2890777A4 (en) | 2015-12-16 |
| EP2890777A1 (en) | 2015-07-08 |
| HUE032520T2 (en) | 2017-10-30 |
| US20150335711A1 (en) | 2015-11-26 |
| RU2542385C2 (ru) | 2015-02-20 |
| CN105308173B (zh) | 2020-03-17 |
| BR112015002522B1 (pt) | 2022-04-05 |
| SI2890777T1 (sl) | 2017-06-30 |
| ZA201500909B (en) | 2016-10-26 |
| US9616103B2 (en) | 2017-04-11 |
| ES2621675T3 (es) | 2017-07-04 |
| CA2881799A1 (en) | 2014-03-06 |
| RU2012137126A (ru) | 2014-03-10 |
| BR112015002522A2 (pt) | 2017-11-07 |
| CN105308173A (zh) | 2016-02-03 |
| WO2014035289A9 (en) | 2014-05-08 |
| CA2881799C (en) | 2019-10-29 |
| MX2015002658A (es) | 2015-09-25 |
| PL2890777T3 (pl) | 2017-07-31 |
| EP2890777B1 (en) | 2017-01-11 |
| WO2014035289A1 (en) | 2014-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Krupkova et al. | Stability of (−)-epigallocatechin gallate and its activity in liquid formulations and delivery systems | |
| Moss | The angiopoietin: Tie 2 interaction: a potential target for future therapies in human vascular disease | |
| Chen et al. | Improving long-term subcutaneous drug delivery by regulating material-bioenvironment interaction | |
| Carretero et al. | Guidelines for the use of acitretin in psoriasis | |
| MA40057A (fr) | Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants | |
| MY188825A (en) | High-concentration monoclonal antibody formulations | |
| MX360980B (es) | Una composición farmacéutica para la estimulación de la angiogénesis. | |
| WO2015149944A3 (en) | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant | |
| MX2016002152A (es) | Metodo para aumentar la expresion de proteinas codificadas por arn. | |
| MX348817B (es) | Metodos para tratar cancer y estados no neoplasicos. | |
| EP2829265A3 (en) | Novel formulations for treatment of migraine | |
| BR112013027674A2 (pt) | "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha". | |
| BR112013004917A2 (pt) | terapias de células tronco alogênicas sistêmicas para tratamento de doenças em animais. | |
| CA3011103A1 (en) | Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone | |
| IN2014DN06920A (es) | ||
| IN2015DN01349A (es) | ||
| MX380429B (es) | Composición para tratar lesiones tisulares. | |
| MY191043A (en) | Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof | |
| NZ606236A (en) | Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease | |
| JOP20170044B1 (ar) | تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو | |
| WO2014122638A3 (en) | Thalidomide and thalidomide analogues for the stimulation of stem cell factor | |
| Paul-Visse et al. | Safety and efficacy of recombinant human platelet derived growth factor BB (rhPDGF-BB) in Parkinson’s disease | |
| WO2016018454A3 (en) | Compositions and methods employing bcl2 and bcl2 family members | |
| Kottmann et al. | A60 LUNG FIBROSIS: ANIMAL MODELS I: The Lactate Dehydrogenase Inhibitor Gossypol Inhibits Bleomycin Induced Pulmonary Fibrosis | |
| EA033539B1 (ru) | Способ стимуляции репаративного ангиогенеза и регенерации соединительной ткани при ее повреждении методом генной терапии с использованием видоспецифичных генов белковых факторов vegf и fgf2 в ветеринарии и генетическая конструкция для реализации заявленного способа |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |